Codexis Inc (CDXS)vsModerna Inc (MRNA)
CDXS
Codexis Inc
$1.47
+1.74%
HEALTHCARE · Cap: $160.43M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 2768% more annual revenue ($2.23B vs $77.68M). CDXS leads profitability with a -39.6% profit margin vs -141.4%. CDXS earns a higher WallStSmart Score of 26/100 (F).
CDXS
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.5%
Fair Value
$5.81
Current Price
$1.47
$4.34 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -68.9% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDXS
CDXS has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CDXS
The primary concerns for CDXS are EPS Growth, Market Cap, PEG Ratio. Debt-to-equity of 2.20 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CDXS carries more volatility with a beta of 2.53 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CDXS generates stronger free cash flow (-11M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CDXS scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Codexis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?